Skip to content
Bored Studies
RecruitingPhase 2

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Rapport Therapeutics Inc. · NCT07219407

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
30
US sites recruiting
7
Study start
December 15, 2025
Record last updated
January 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Being studied: RAP-219

Conditions: Focal Epilepsy; Epilepsy; Refractory Focal Epilepsy; Seizure; Focal Seizure; Focal Onset Seizure

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.
  • Diagnosis of refractory focal epilepsy
  • Stable RNS(c) system settings
  • A demonstrated history of compliance with RNS(c) system data interrogation and upload
  • Good overall health other than focal epilepsy, per Investigator.
  • BMI ≥ 18 kg/m\^2 and ≤ 45 kg/m\^2
  • Willing and able to adhere to all aspects of the protocol.

Exclusion Criteria

  • Known of hypersensitivity to RAP-219
  • Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator
  • Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods

Recruiting US locations

Study contacts (from the official record)

  • Daniela Moreno · (857) 323-9048 · dmoreno@rapportrx.com
  • Beth Bowers · (857) 323-9048 · bbowers@rapportrx.com
All neurology studies in Idaho →
A Long-term Study of the Safety and Effectiveness of RAP-219 in… (NCT07219407) | Bored Studies